TY - JOUR
T1 - Phase i immunotherapy trial with two chimeric HER-2 B-Cell peptide vaccines emulsified in montanide ISA 720VG and Nor-MDP adjuvant in patients with advanced solid tumors
AU - Bekaii-Saab, Tanios
AU - Wesolowski, Robert
AU - Ahn, Daniel H.
AU - Wu, Christina
AU - Mortazavi, Amir
AU - Lustberg, Maryam
AU - Ramaswamy, Bhuvaneswari
AU - Fowler, Jeffrey
AU - Wei, Lai
AU - Overholser, Jay
AU - Kaumaya, Pravin T.P.
N1 - Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019/6/15
Y1 - 2019/6/15
N2 - Purpose: This first-in-human phase I study (NCT 01417546) evaluated the safety profile, optimal immunologic/ biological dose (OID/OBD), and immunogenicity of the combination of two peptide B-cell epitope vaccines engineered to represent the trastuzumab- and pertuzumabbinding sites. Although trastuzumab and pertuzumab have been approved for clinical use, patients often develop resistance to these therapies. We have advanced a new paradigm in immunotherapy that focuses on humoral responses based on conformational B-cell epitope vaccines. Patients and Methods: The vaccine is comprised of two chimeric HER-2 B-cell peptide vaccines incorporating a "promiscuous T-cell epitope." Patients were immunized with the vaccine constructs emulsified with nor-muramyldipeptide adjuvant in a water-in-oil Montanide ISA 720VG vehicle. Eligible patients with metastatic and/or recurrent solid tumors received three inoculations every 3 weeks. Results: Forty-nine patients with a median of 4 prior lines of chemotherapy received at least 1 vaccination. Twenty-eight patients completed the 3 vaccination regimens. Six patients received 1 six-month boost after the regimen, and one patient received 7 six-month boosts. No serious adverse reactions or dose-limiting toxicities were observed. The vaccine was well tolerated with dose level 2 as the recommended phase II dose. The most common related toxicity in all patients was injection-site reactions (24%). Two patients had a partial response, 14 had stable disease, and 19 had progressive disease. Conclusions: The study vaccine is safe, exhibits antitumor activity, and shows preliminary indication that peptide vaccination may avoid therapeutic resistance and offer a promising alternative to monoclonal antibody therapies.
AB - Purpose: This first-in-human phase I study (NCT 01417546) evaluated the safety profile, optimal immunologic/ biological dose (OID/OBD), and immunogenicity of the combination of two peptide B-cell epitope vaccines engineered to represent the trastuzumab- and pertuzumabbinding sites. Although trastuzumab and pertuzumab have been approved for clinical use, patients often develop resistance to these therapies. We have advanced a new paradigm in immunotherapy that focuses on humoral responses based on conformational B-cell epitope vaccines. Patients and Methods: The vaccine is comprised of two chimeric HER-2 B-cell peptide vaccines incorporating a "promiscuous T-cell epitope." Patients were immunized with the vaccine constructs emulsified with nor-muramyldipeptide adjuvant in a water-in-oil Montanide ISA 720VG vehicle. Eligible patients with metastatic and/or recurrent solid tumors received three inoculations every 3 weeks. Results: Forty-nine patients with a median of 4 prior lines of chemotherapy received at least 1 vaccination. Twenty-eight patients completed the 3 vaccination regimens. Six patients received 1 six-month boost after the regimen, and one patient received 7 six-month boosts. No serious adverse reactions or dose-limiting toxicities were observed. The vaccine was well tolerated with dose level 2 as the recommended phase II dose. The most common related toxicity in all patients was injection-site reactions (24%). Two patients had a partial response, 14 had stable disease, and 19 had progressive disease. Conclusions: The study vaccine is safe, exhibits antitumor activity, and shows preliminary indication that peptide vaccination may avoid therapeutic resistance and offer a promising alternative to monoclonal antibody therapies.
UR - http://www.scopus.com/inward/record.url?scp=85067442599&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067442599&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-3997
DO - 10.1158/1078-0432.CCR-18-3997
M3 - Article
C2 - 30804020
AN - SCOPUS:85067442599
SN - 1078-0432
VL - 25
SP - 3495
EP - 3507
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -